子宫癌肉瘤:从病理到实践
本文综述子宫癌肉瘤(UCS)的病理特征、分子靶点、正在进行的临床试验及早期和晚期/复发疾病的治疗。UCS 是一种罕见但侵袭性强的双相癌,癌成分驱动其侵袭性。早期疾病缺乏 3 级证据,但回顾性数据支持辅助治疗;GOG 261 结果支持紫杉醇联合卡铂用于 UCS。目前手术切除和传统细胞毒性化疗仍是标准治疗。
要点
- UCS 为双相癌,癌成分驱动其侵袭性。
- 早期 UCS 缺乏 3 级证据,回顾性数据支持辅助治疗。
- GOG 261 支持紫杉醇联合卡铂用于 UCS 治疗。
核心结论
- 正在进行的子宫内膜癌临床试验现已纳入 UCS 患者,结合分子分型进展将为 UCS 患者提供更多治疗选择。
- 在此之前,手术切除和传统细胞毒性化疗仍是标准治疗。
研究设计与样本
- 本综述基于 2019 年 NRG 肿瘤学组夏季研讨会专家报告及广泛文献检索,检索 MEDLINE 和 ClinicalTrials.gov,不限年份和研究设计但限英文。
主要发现
- UCS 是一种罕见癌症,呈双相性,癌成分驱动其侵袭性。
- 早期疾病缺乏 3 级证据,但回顾性数据提示需要辅助治疗。
- GOG 261 的结果为治疗策略提供了重要信息,包括紫杉醇联合卡铂用于 UCS。
- 正在开展临床试验研究 UCS 的新靶向药物。
临床怎么用
- 手术切除联合传统细胞毒性化疗仍是 UCS 的标准治疗。
- 早期 UCS 可考虑辅助治疗,但需结合回顾性证据和个体情况。
- 紫杉醇联合卡铂可作为 UCS 的化疗选择。
局限性
- 早期 UCS 缺乏 3 级证据,治疗数据稀疏。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Uterine carcinosarcoma (UCS) is a rare but aggressive cancer. In early-stage disease data guiding treatment is sparse. The purpose of this review is to summarize the findings from the 2019 NRG oncology group summer symposium meeting as well as a review of the current literature, with a particular focus on molecular targets, ongoing clinical trials, and treatment of early and advanced/recurrent disease. METHODS: A combination of expert presentations and an extensive literature search was undertaken to summarize the literature in this review. MEDLINE was queried for peer-reviewed publications on UCS. This search was not limited by year or study design, but was limited to English language publications. ClinicalTrials.gov was queried for ongoing trials in UCS. RESULTS: UCS is a rare cancer that is biphasic, with the carcinomatous component driving its aggressive nature. Level 3 evidence regarding early stage disease is lacking, but retrospective data suggests adjuvant therapy is warranted. The recent results of GOG 261 have contributed valuable information towards treatment strategy, including use of paclitaxel and carboplatin for UCS. Clinical trials are ongoing to investigate new targeted agents in UCS. CONCLUSION: Ongoing endometrial cancer clinical trials now include UCS patients. In combination with advances in molecular profiling, this will provide patients with UCS improved therapeutic options. Until that time, surgical resection and traditional cytotoxic chemotherapy remains standard of care.
引用
- Toboni MD, Crane EK, Brown J, et al. Uterine carcinosarcomas: From pathology to practice. Gynecol Oncol. 2021. PMID: 34030871. doi:10.1016/j.ygyno.2021.05.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。